The biological role of metabolic reprogramming in pancreatic cancer
Tatsunori Suzuki, Motoyuki Otsuka, Takahiro Seimiya, Takuma Iwata, Takahiro Kishikawa, Kazuhiko Koike
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease and highly resistant to all forms of therapy. PDAC cells reprogram their metabolism extensively to promote their survival and growth. Reflecting the vital role of altered metabolism, experimental and clinical trials targeting the rewired metabolism are currently underway. In this review, we summarize the vital role of metabolic reprogramming in the development of PDAC and the future of novel therapeutic applications.
Topics & Concepts
Pancreatic cancerReprogrammingCancerBiologyMedicineCancer researchInternal medicineGeneticsGeneCancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology ResearchMetabolism, Diabetes, and Cancer